Related Experiment Video

Updated: Sep 20, 2026

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

JNK: a new therapeutic target for diabetes

Brydon L Bennett1, Yoshitaka Satoh, Alan J Lewis

  • 1Celgene Corporation, 4550 Towne Centre Court, San Diego, CA 92121, USA. bbennett@celgene.com

Current Opinion in Pharmacology
|August 7, 2003
PubMed

Insights

Jun N-terminal kinase (JNK) is crucial for immune responses but may also drive diabetes. Inhibiting JNK could offer new therapeutic strategies for metabolic diseases like obesity and insulin resistance.

Area of Science:

  • Molecular Biology
  • Immunology
  • Metabolic Disease Research

Background:

  • Jun N-terminal kinase (JNK) regulates the transcription factor AP-1, a key player in immune response gene expression.
  • JNK inhibitors have been pursued for chronic inflammatory diseases.
  • Emerging evidence links activated JNK to diabetes, insulin resistance, and obesity.

Purpose of the Study:

  • To explore the role of activated Jun N-terminal kinase (JNK) in the development of diabetes.
  • To investigate the mechanisms by which JNK signaling may promote metabolic dysfunction.
  • To re-evaluate JNK as a therapeutic target beyond inflammatory conditions.

Main Methods:

  • Review of genetic evidence linking JNK to metabolic disorders.
  • Analysis of emerging pharmacological data on JNK activity.
  • Exploration of stress-activated protein kinase pathways.

Main Results:

  • Activated JNK signaling is implicated in the pathogenesis of diabetes.
  • Multiple mechanisms suggest JNK's role in promoting insulin resistance and obesity.
  • JNK's function extends beyond immune regulation to metabolic control.

Conclusions:

  • Jun N-terminal kinase (JNK) plays a critical role in metabolic diseases, including diabetes, insulin resistance, and obesity.
  • Targeting JNK may represent a novel therapeutic approach for these conditions.
  • Further research is warranted to elucidate the multifaceted roles of JNK in health and disease.

Related Concept Videos

Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Diabetes Mellitus: Introduction01:26

Diabetes Mellitus: Introduction

Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...